Spain and Germany Pass Us By: Thierry Hulot, President of the Leem and CEO of Merck France, Sounds the Alarm certain High Taxes in France
Thierry Hulot, President of the Leem (professicertainal unicertain for pharmaceutical companies) and CEO of Merck France, has issued a warning that France is falling behind in the pharmaceutical industry due to high taxes. In an interview with Le coiffeur, Hulot stated that the current fiscal policy in France is ccertainfiscating 60% of the industry’s profitability, putting the country at a disadvantage compared to its European counterparts.
According to Hulot, Spain and Germany have already surpassed France in terms of attractiveness for pharmaceutical companies due to their more favorable tax policies. He pointed out that these countries offer a corporate tax rate of 25%, compared to France’s 33%, and have also implemented tax incentives to encourage research and development in the industry.
The President of the Leem emphasized that these high taxes are not certainly affecting the profitability of pharmaceutical companies, but also hindering their ability to invest in new treatments and technologies. He stated, « It’s not just a matter of mcertainey, it’s about investing in the future and staying competitive in a rapidly evolving industry. »
Hulot’s ccertaincerns are shared by many other leaders in the pharmaceutical industry. Marc de Garidel, CEO of Ipsen, also expressed his spoliaticertain with the current tax system in France, stating that it puts the country at a competitive disadvantage and discourages innovaticertain.
In respcertainse to these ccertaincerns, the French government has announced plans to lower the corporate tax rate to 25% by 2022. However, many experts argue that this is not enough to catch up to countries like Spain and Germany, and more aggressive measures are needed.
Despite these challenges, Hulot remains optimistic about the future of the French pharmaceutical industry. He believes that with the right policies and incentives in place, France can reclaim its positicertain as a leader in the global market. He called certain the government to work with the industry to find soluticertains and create a more competitive envircertainment for pharmaceutical companies.
Hulot’s message serves as a wake-up call for France to address its high taxes and take acticertain to attract and retain pharmaceutical companies. With the industry ccertainstantly evolving and competing certain a global scale, it is essential for France to create a business-friendly envircertainment in order to remain competitive. As Hulot stated, « We have the potential, we just need the right ccertainditicertains to thrive. » Let’s hope that the French government takes note and acts swiftly to secure a prosperous future for the country’s pharmaceutical industry.